Literature DB >> 11711483

Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.

S N Makoni1.   

Abstract

Abciximab, heparin, and clopidogrel are often used together in the setting of coronary syndromes. These drugs are associated with thrombocytopenia and it is important to quickly discriminate the cause of this complication as it has implications for the management of thrombocytopenia and the coronary syndrome. This case highlights some of the dilemmas that may arise as no test can definitively identify the offending drug, and stopping these drugs can affect the outcome of the coronary event including stent thrombosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711483      PMCID: PMC1730004          DOI: 10.1136/heart.86.6.e18

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia.

Authors:  M B Holmes; S Kabbani; M W Watkins; R W Battle; D J Schneider
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

2.  Hemolytic uremic syndrome in a patient treated with clopidogrel.

Authors:  P H Oomen; J E Tulleken; J G Zijlstra
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

Review 3.  Safe use of platelet GP IIb/IIIa inhibitors.

Authors:  J J Ferguson; D J Kereiakes; A A Adgey; K A Fox; W B Hillegass; M Pfisterer; C Vassanelli
Journal:  Am Heart J       Date:  1998-04       Impact factor: 4.749

4.  Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.

Authors:  D J Kereiakes; S D Berkowitz; A M Lincoff; J E Tcheng; K Wolski; R Achenbach; R Melsheimer; K Anderson; R M Califf; E J Topol
Journal:  Am Heart J       Date:  2000-07       Impact factor: 4.749

5.  Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

Authors:  S D Berkowitz; R A Harrington; M M Rund; J E Tcheng
Journal:  Circulation       Date:  1997-02-18       Impact factor: 29.690

6.  Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Authors:  A M Lincoff; D B Mark; J E Tcheng; R M Califf; M V Bala; K M Anderson; L Davidson-Ray; J D Knight; C F Cabot; E J Topol
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

7.  Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.

Authors:  H Dasgupta; J C Blankenship; G C Wood; C M Frey; S L Demko; F J Menapace
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

Review 8.  Clopidogrel.

Authors:  A J Coukell; A Markham
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

  8 in total
  3 in total

1.  Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.

Authors:  Todd Golden; Sehem Ghazala; Rita Wadeea; Shilpa Junna
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration.

Authors:  Yuan-Lin Guo; Jian-Jun Li; Jin-Qing Yuan; Xue-Wen Qin; Xin Zheng; Chao-Wei Mu; Yi-Hong Hua
Journal:  World J Cardiol       Date:  2010-06-26

3.  Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.

Authors:  Soonyoung Park; Jooyoung Lee; Sang Yeub Lee; Jang-Whan Bae; Kyung-Kuk Hwang; Dong-Woon Kim; Myeong-Chan Cho; Sang Min Kim
Journal:  Korean Circ J       Date:  2013-08-31       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.